Opposite changes in serum soluble CD8 in patients at the active stages of Graves' and Hashimoto's diseases.

Serum concentrations of soluble CD8 (sCD8) were examined by enzyme immunoassay in 154 patients with autoimmune thyroid diseases and 46 healthy controls. The numbers of peripheral CD8+ cells were also examined in the same subjects by flow cytometry. The serum concentrations of sCD8 were increased in patients with stimulative thyrotoxicosis caused by active Graves' disease, and decreased in patients with transient destructive thyrotoxicosis caused by the aggravation of Hashimoto's disease, and normal in euthyroid and hypothyroid patients with Graves' or Hashimoto's disease. The ratios of serum sCD8 levels to the numbers of CD8+ cells were increased in thyrotoxic patients with active Graves' disease, but not with active Hashimoto's disease, suggesting an increase in sCD8 production by CD8+ cells in active Graves' disease. The serum concentrations of sCD8 were correlated with the serum levels of thyrotropin receptor antibody (TRAb) and thyroid hormones in Graves' disease. These data indicate that serum sCD8 proteins change in opposite directions in the active stages of Graves' and Hashimoto's diseases, and may represent the disease activities.

[1]  P. Kallio,et al.  Soluble CD antigen (cytokine) expression in various hyperthyroid states and use in the assessment of propylthiouracil treatment. , 1994, Journal of Laboratory and Clinical Medicine.

[2]  J. Klinenberg,et al.  Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. , 1994, Journal of immunology.

[3]  D. Cucinotta,et al.  High serum levels of soluble CD8 in insulin‐dependent diabetes , 1994, Clinical and experimental immunology.

[4]  N. Farid,et al.  Serum soluble CD8 concentration is an indicator of disease activity in patients with Graves' disease. , 1994, Thyroid : official journal of the American Thyroid Association.

[5]  F. Matsuzuka,et al.  Intrathyroidal lymphocyte subsets, including unusual CD4+ CD8+ cells and CD3loTCRαβ1o/‐CD4−CD8−cells, in autoimmune thyroid disease , 1993 .

[6]  T. Mak,et al.  CD8 is critically involved in lymphocyte activation by a T. brucei brucei-released molecule , 1993, Cell.

[7]  F. Matsuzuka,et al.  Decreases in αβ T cell receptor negative T cells and CD8 cells, and an increase in CD4 + CD8+ cells in active Hashimoto's disease and subacute thyroiditis , 1992 .

[8]  J. Riordan,et al.  Membrane proteins with soluble counterparts: role of proteolysis in the release of transmembrane proteins. , 1991, Biochemistry.

[9]  F. Matsuzuka,et al.  Marked increase of CD5 + B cells in hyperthyroid Graves' disease. , 1989, Clinical and experimental immunology.

[10]  D. Griffin,et al.  Immune activation in measles. , 1989, The New England journal of medicine.

[11]  M. Brown,et al.  Soluble CD8 during T cell activation. , 1989, Journal of immunology.

[12]  M. Grieco,et al.  Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations , 1989, Journal of clinical microbiology.

[13]  H. Gerstein,et al.  The decrease in non-specific suppressor T lymphocytes in female hyperthyroid Graves' disease is secondary to the hyperthyroidism. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[14]  T. Davies,et al.  An intrathyroidal T-cell clone specifically cytotoxic for human thyroid cells. , 1987, Immunology.

[15]  T. Davies,et al.  Intrathyroidal T cell clones from patients with autoimmune thyroid disease. , 1987, The Journal of clinical endocrinology and metabolism.

[16]  S. Levy,et al.  Spontaneous release of the Leu-2 (T8) molecule from human T cells , 1983, The Journal of experimental medicine.

[17]  L. Degroot,et al.  Studies on suppressor cell function in thyroid diseases. , 1979, The Journal of clinical endocrinology and metabolism.